EP Patent

EP2959901A1 — Pharmaceutical combinations of sofosbuvir and ribavirin

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2015-12-30 · 10y expired

What this patent protects

This invention is a novel pharmaceutical composition comprising sofosbuvir and ribavirin and at least one pharmaceutically acceptable excipient for use in the treatment of hepatitis C virus infections, chronic hepatitis C (CHC), hepatocellular carcinoma or patients with end-stage…

USPTO Abstract

This invention is a novel pharmaceutical composition comprising sofosbuvir and ribavirin and at least one pharmaceutically acceptable excipient for use in the treatment of hepatitis C virus infections, chronic hepatitis C (CHC), hepatocellular carcinoma or patients with end-stage liver disease awaiting liver transplantation.

Drugs covered by this patent

Patent Metadata

Patent number: EP2959901A1
Jurisdiction: EP
Classification: —
Expires: 2015-12-30
Drug substance claim: No
Drug product claim: No
Assignee: Sanovel Ilac Sanayi ve Ticaret AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.